According to filings with the U.S. Securities and Exchange Commission, Nanochon is raising up to $4,223,097.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Nanochon
At present, there is an established clinical standard for treating joint disease: the total joint replacement. Yet, while the surgical devices and techniques used to implant them have been largely perfected, todays standard replacement joints are very invasive, and not permanent. The lifespan of common replacement joints limits their effective use in patients aged 55 or older. This leaves patients between ages 18 and 55 suffering from cartilage damage, traumatic injury, or early stage cartilage loss with limited treatment options. Nanochon, is developing an implant designed to not only replace lost and damaged cartilage, but also to encourage new tissue growth. Using 3-D printing and a novel material, the Nanochon implant is a sturdy medical advancement that is both an orthopedic load bearing implant as well a tissue growth scaffold. The Nanochon implant has the potential to deliver faster and more successful recoveries for patients, while reducing costs to health providers, payers, and patients. Nanochons aim is to set a new clinical standard for cartilage restoration.

To learn more about Nanochon, visit https://nanochon.com/
Nanochon Linkedin Page: https://www.linkedin.com/company/nanochon/

Contact:
Benjamin Holmes, Chief Executive Officer
703-994-6099
https://www.linkedin.com/in/bbhceo/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.